News coverage about PTC Therapeutics (NASDAQ:PTCT) has trended positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. PTC Therapeutics earned a news impact score of 0.30 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 44.7556319402175 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news headlines that may have impacted Accern Sentiment’s rankings:

PTC Therapeutics (NASDAQ PTCT) opened at 20.55 on Tuesday. PTC Therapeutics has a one year low of $4.03 and a one year high of $22.00. The stock has a 50 day moving average price of $19.64 and a 200 day moving average price of $14.98. The company’s market cap is $848.80 million.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.89) by $0.45. The firm had revenue of $47.96 million during the quarter, compared to analyst estimates of $28.78 million. PTC Therapeutics had a negative net margin of 88.43% and a negative return on equity of 81.84%. The company’s revenue for the quarter was up 206.9% on a year-over-year basis. During the same quarter last year, the business posted ($1.14) EPS. On average, equities analysts anticipate that PTC Therapeutics will post ($2.35) EPS for the current fiscal year.

Several analysts have issued reports on PTCT shares. ValuEngine downgraded PTC Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, September 7th. Barclays PLC reissued a “hold” rating and issued a $22.00 price target on shares of PTC Therapeutics in a research note on Friday. Citigroup Inc. reissued a “buy” rating and issued a $17.00 price target (down previously from $28.00) on shares of PTC Therapeutics in a research note on Thursday, July 20th. Zacks Investment Research raised PTC Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research note on Wednesday, August 30th. Finally, BidaskClub downgraded PTC Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $17.10.

WARNING: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Insider Buying and Selling by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Stock Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related stocks with our FREE daily email newsletter.